AU2015249887A1 - Novel anti-RNF43 antibodies and methods of use - Google Patents

Novel anti-RNF43 antibodies and methods of use Download PDF

Info

Publication number
AU2015249887A1
AU2015249887A1 AU2015249887A AU2015249887A AU2015249887A1 AU 2015249887 A1 AU2015249887 A1 AU 2015249887A1 AU 2015249887 A AU2015249887 A AU 2015249887A AU 2015249887 A AU2015249887 A AU 2015249887A AU 2015249887 A1 AU2015249887 A1 AU 2015249887A1
Authority
AU
Australia
Prior art keywords
antibody
rnf43
seq
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015249887A
Other languages
English (en)
Inventor
Monette Aujay
Mandy BOONTANRART
Scott J. Dylla
David Liu
Deepti ROKKAM
Samuel A. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Stemcentrx LLC
Original Assignee
AbbVie Stemcentrx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Stemcentrx LLC filed Critical AbbVie Stemcentrx LLC
Publication of AU2015249887A1 publication Critical patent/AU2015249887A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2015249887A 2014-04-21 2015-04-21 Novel anti-RNF43 antibodies and methods of use Abandoned AU2015249887A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982294P 2014-04-21 2014-04-21
US61/982,294 2014-04-21
PCT/US2015/026904 WO2015164392A2 (en) 2014-04-21 2015-04-21 Novel antii-rnf43 antibodies and methods of use

Publications (1)

Publication Number Publication Date
AU2015249887A1 true AU2015249887A1 (en) 2016-11-03

Family

ID=54333409

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015249887A Abandoned AU2015249887A1 (en) 2014-04-21 2015-04-21 Novel anti-RNF43 antibodies and methods of use

Country Status (18)

Country Link
US (1) US20170073430A1 (enExample)
EP (1) EP3134121A4 (enExample)
JP (1) JP2017518040A (enExample)
KR (1) KR20170010764A (enExample)
CN (1) CN106714831A (enExample)
AU (1) AU2015249887A1 (enExample)
BR (1) BR112016024525A2 (enExample)
CA (1) CA2946308A1 (enExample)
CL (2) CL2016002667A1 (enExample)
CR (1) CR20160486A (enExample)
DO (1) DOP2016000283A (enExample)
EA (1) EA201692100A8 (enExample)
IL (1) IL248399A0 (enExample)
MA (1) MA39896A (enExample)
MX (1) MX2016013857A (enExample)
PH (1) PH12016502061A1 (enExample)
SG (1) SG11201608715WA (enExample)
WO (1) WO2015164392A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4279513A3 (en) 2010-11-30 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
TW201800420A (zh) * 2016-05-20 2018-01-01 艾伯維史坦森特瑞斯有限責任公司 抗ascl1抗體及使用方法
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
EP3574019A4 (en) * 2017-01-26 2021-03-03 Surrozen, Inc. TISSUE-SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND THEIR USES
US20200123256A1 (en) * 2017-05-02 2020-04-23 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US12215154B2 (en) 2018-01-19 2025-02-04 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting γδ T cells with chimeric antigen receptors
CA3104868A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
CN113508127A (zh) * 2018-11-06 2021-10-15 阿尔萨泰克公司 神经变性疾病的基于细胞的基因疗法
US11713461B2 (en) 2019-06-21 2023-08-01 Regeneran Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors
KR20230109668A (ko) 2020-11-16 2023-07-20 서로젠 오퍼레이팅, 인크. 간-특이적 Wnt 신호 증강 분자 및 그의 용도
WO2022109443A1 (en) * 2020-11-23 2022-05-27 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
WO2022169872A1 (en) * 2021-02-03 2022-08-11 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
JP2024510291A (ja) * 2021-03-16 2024-03-06 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫疾患を治療するための二機能性分子
CN113372447A (zh) * 2021-05-26 2021-09-10 重庆中元汇吉生物技术有限公司 抗pivka-ii单克隆抗体及其应用
WO2024025878A2 (en) * 2022-07-25 2024-02-01 Memorial Sloan-Kettering Cancer Center Manufacturing processes for adoptive cell therapies
CN116120444A (zh) * 2023-02-28 2023-05-16 中国人民解放军军事科学院防化研究院 一种用于检测SARS-CoV-2病毒N蛋白的纳米抗体及检测卡制备
CN117801108B (zh) * 2023-12-06 2024-06-07 无锡傲锐东源生物科技有限公司 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
CN118652345B (zh) * 2024-06-28 2025-04-15 杭州华葵金配生物科技有限公司 幽门螺旋杆菌b型尿素酶抗体及其应用
CN119462949B (zh) * 2025-01-09 2025-04-01 中国农业科学院农业质量标准与检测技术研究所 一种抗β-内酰胺酶的抗体或其抗原结合片段、生物产品及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1513934T1 (sl) * 2002-06-06 2011-06-30 Oncotherapy Science Inc Geni in polipeptidi, povezani s humanimi raki kolona
US8524865B2 (en) * 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP3653222A1 (en) * 2011-10-14 2020-05-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
RU2017120287A (ru) * 2012-02-28 2018-11-15 АйАрЭм ЭлЭлСи ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43

Also Published As

Publication number Publication date
EA201692100A1 (ru) 2017-02-28
CL2017003240A1 (es) 2018-06-01
US20170073430A1 (en) 2017-03-16
BR112016024525A2 (pt) 2017-10-10
PH12016502061A1 (en) 2016-12-19
EA201692100A8 (ru) 2018-11-30
CA2946308A1 (en) 2015-10-29
EP3134121A4 (en) 2017-11-08
MA39896A (fr) 2017-03-01
WO2015164392A3 (en) 2015-12-23
JP2017518040A (ja) 2017-07-06
CL2016002667A1 (es) 2017-07-07
WO2015164392A2 (en) 2015-10-29
CR20160486A (es) 2017-02-20
IL248399A0 (en) 2016-11-30
CN106714831A (zh) 2017-05-24
DOP2016000283A (es) 2016-11-30
EP3134121A2 (en) 2017-03-01
MX2016013857A (es) 2017-07-14
SG11201608715WA (en) 2016-11-29
WO2015164392A8 (en) 2016-12-29
KR20170010764A (ko) 2017-02-01

Similar Documents

Publication Publication Date Title
US9777071B2 (en) Anti-DPEP3 antibodies and methods of use
US10053511B2 (en) Anti-claudin antibodies and methods of use
US10428156B2 (en) Anti-MFI2 antibodies and methods of use
US20170073430A1 (en) Novel anti-rnf43 antibodies and methods of use
US20190083645A1 (en) Novel anti-claudin antibodies and methods of use
US20180327506A1 (en) Novel anti-emr2 antibodies and methods of use
US20210261670A1 (en) Novel anti-bmpr1b antibodies and methods of use
WO2015095766A2 (en) Novel anti-lingo1 antibodies and methods of use
AU2016378744A1 (en) Novel anti-UPK1B antibodies and methods of use
WO2018107109A1 (en) Novel anti-kremen2 antibodies and methods of use
US20190016812A1 (en) Novel anti-tnfsf9 antibodies and methods of use
AU2017261369A1 (en) Novel anti-TNFRSF21 antibodies and methods of use

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ NOVEL ANTI-RNF43 ANTIBODIES AND METHODS OF USE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BOONTANRART, MANDY; ROKKAM, DEEPTI; LIU, DAVID; DYLLA, SCOTT J.; AUJAY, MONETTE AND WILLIAMS, SAMUEL A.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application